M&T Bank Corp Increases Position in Inhibrx, Inc. (NASDAQ:INBX)

M&T Bank Corp grew its holdings in Inhibrx, Inc. (NASDAQ:INBXGet Rating) by 182.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,172 shares of the company’s stock after acquiring an additional 21,429 shares during the period. M&T Bank Corp owned about 0.08% of Inhibrx worth $376,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of INBX. DekaBank Deutsche Girozentrale grew its stake in shares of Inhibrx by 10.0% in the first quarter. DekaBank Deutsche Girozentrale now owns 26,400 shares of the company’s stock worth $590,000 after acquiring an additional 2,400 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Inhibrx by 1,012.0% in the first quarter. Nisa Investment Advisors LLC now owns 11,120 shares of the company’s stock worth $248,000 after acquiring an additional 10,120 shares in the last quarter. Victory Capital Management Inc. grew its stake in shares of Inhibrx by 20.5% in the first quarter. Victory Capital Management Inc. now owns 99,951 shares of the company’s stock worth $2,157,000 after acquiring an additional 16,998 shares in the last quarter. IndexIQ Advisors LLC acquired a new position in shares of Inhibrx in the first quarter worth $384,000. Finally, Swiss National Bank grew its stake in shares of Inhibrx by 5.6% in the first quarter. Swiss National Bank now owns 22,500 shares of the company’s stock worth $501,000 after acquiring an additional 1,200 shares in the last quarter. Institutional investors and hedge funds own 67.27% of the company’s stock.

Insider Activity at Inhibrx

In related news, insider Brendan P. Eckelman sold 40,000 shares of the business’s stock in a transaction on Tuesday, October 4th. The shares were sold at an average price of $27.82, for a total value of $1,112,800.00. Following the completion of the sale, the insider now directly owns 2,235,553 shares of the company’s stock, valued at $62,193,084.46. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, insider Brendan P. Eckelman sold 40,000 shares of the business’s stock in a transaction on Tuesday, October 4th. The shares were sold at an average price of $27.82, for a total value of $1,112,800.00. Following the completion of the sale, the insider now directly owns 2,235,553 shares of the company’s stock, valued at $62,193,084.46. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Global Investors Lp Viking purchased 1,333,333 shares of Inhibrx stock in a transaction that occurred on Friday, October 7th. The stock was bought at an average cost of $30.00 per share, with a total value of $39,999,990.00. Following the completion of the transaction, the insider now owns 2,427,307 shares of the company’s stock, valued at $72,819,210. The disclosure for this purchase can be found here. Insiders sold a total of 115,500 shares of company stock valued at $3,508,775 over the last ninety days. Insiders own 25.80% of the company’s stock.

Inhibrx Stock Performance

Shares of INBX stock opened at $32.80 on Tuesday. The company has a current ratio of 6.05, a quick ratio of 7.50 and a debt-to-equity ratio of 4.16. The firm has a fifty day moving average price of $24.76 and a 200 day moving average price of $19.00. The company has a market cap of $1.43 billion, a P/E ratio of -10.19 and a beta of 3.25. Inhibrx, Inc. has a 12 month low of $7.67 and a 12 month high of $45.99.

Wall Street Analyst Weigh In

Several research firms have commented on INBX. Credit Suisse Group dropped their price target on shares of Inhibrx from $48.00 to $46.00 and set an “outperform” rating for the company in a research note on Tuesday, November 8th. Evercore ISI boosted their target price on shares of Inhibrx from $54.00 to $60.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 5th. Finally, JMP Securities reiterated a “buy” rating and set a $40.00 target price on shares of Inhibrx in a research note on Wednesday, October 5th.

Inhibrx Company Profile

(Get Rating)

Inhibrx, Inc, a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.

See Also

Want to see what other hedge funds are holding INBX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inhibrx, Inc. (NASDAQ:INBXGet Rating).

Institutional Ownership by Quarter for Inhibrx (NASDAQ:INBX)

Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.